The Ottawa Hospital Research Institute
Welcome,         Profile    Billing    Logout  
 18 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Freedman, Mark S
CALLIPER, NCT05054140 / 2021-000048-23: Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Active, not recruiting
2
450
Europe, Canada, US, RoW
IMU-838, Vidofludimus calcium, Placebo matching IMU-838, Placebo Arm
Immunic AG
Multiple Sclerosis
01/25
01/25
Carrier, Marc
SAFE-SSPE, NCT04263038: Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

Recruiting
4
276
Europe, Canada
Rivaroxaban, Placebo
Drahomir Aujesky, University of Bern, Schweizerischer Nationalfonds, Leiden University Medical Center, The Ottawa Hospital, Bayer
Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases, Cardiovascular Diseases, Respiratory Tract Diseases, Venous Thromboembolism, Anticoagulant-induced Bleeding, Bleeding
05/26
05/26
API-CAT, NCT03692065 / 2017-003342-25: STUDY for APIxaban Cancer Associated Thrombosis

Completed
3
1767
Europe, Canada
Apixaban 5 MG, Apixaban 2.5 MG
Assistance Publique - Hôpitaux de Paris, Bristol-Myers Squibb
Cancer-associated Thrombosis
09/24
10/24
ATTACC-CAP, NCT05848713: AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Recruiting
3
4000
Canada, US, RoW
Heparin
University of Manitoba, Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI
Community-acquired Pneumonia
03/28
03/29
Dowlatshahi, Dariush
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
Dowlatshahi, Dar
FASTEST, NCT03496883: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Recruiting
3
860
Europe, Canada, Japan, US
Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo
Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)
Intracerebral Hemorrhage
01/28
01/28
Fisette-Paulhus, Isabelle
REACH, NCT05397470 / 2022-000389-16: Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Terminated
3
260
Europe, Canada, US
Losmapimod, Placebo oral tablet
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
11/24
11/24
MOVE FSHD, NCT04635891: Motor Outcomes to Validate Evaluations in FSHD

Recruiting
N/A
450
Europe, Canada, US
University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche
FSHD
12/26
01/27

Download Options